Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

By B. Ference, J. Robinson, Robert D. Brook, Alberico L. Catapano, M. J. Chapman, D. Neff, S. Voros, R. Giugliano, G. Smith, S. Fazio and 1 more. New England Journal of Medicine, 2016

670 citations recorded by the source corpus.

Subfields: Emergency Medicine, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/22cff85b2ee9de016d298f503d73cc8dda395349

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Surgery

Citations in the corpus

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDL-C, because—on average—the reduction in LDL-C and LDL particles will be concordant.(34,50,54,55) In contrast, the clinical benefit of therapies that lower ”
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, result): “Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent lo”
Mendelian randomization for cardiovascular diseases: principles and applications (2023, positive): “95,104,105 As a further example, cis -MR analyses have been performed to predict the cardiovascular effects of lowering circulating levels of Lp(a).”